NANOVIRICIDES NEW DL-01
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product for… Read more
NANOVIRICIDES NEW DL-01 (NV3P) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, NANOVIRICIDES NEW DL-01 (NV3P) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
NANOVIRICIDES NEW DL-01 - Net Assets Trend (None–None)
This chart illustrates how NANOVIRICIDES NEW DL-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NANOVIRICIDES NEW DL-01 (None–None)
The table below shows the annual net assets of NANOVIRICIDES NEW DL-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to NANOVIRICIDES NEW DL-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
NANOVIRICIDES NEW DL-01 Competitors by Market Cap
The table below lists competitors of NANOVIRICIDES NEW DL-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gensource Potash Corporation
PINK:AGCCF
|
$18.03 Million |
|
ClimateRock Class A Ordinary Shares
NASDAQ:CLRC
|
$18.03 Million |
|
Beamtree Holdings Ltd
AU:BMT
|
$18.03 Million |
|
Globalsat Worldcom
TWO:3499
|
$18.03 Million |
|
Dotz Nano Limited
OTCQB:DTZZF
|
$18.02 Million |
|
Upsales Technology AB
ST:UPSALE
|
$18.02 Million |
|
Astino Bhd
KLSE:7162
|
$18.01 Million |
|
Decibel Cannabis Company Inc
OTCQB:DBCCF
|
$18.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NANOVIRICIDES NEW DL-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares NANOVIRICIDES NEW DL-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently NANOVIRICIDES NEW DL-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares NANOVIRICIDES NEW DL-01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NANOVIRICIDES NEW DL-01 (NV3P) | €- | N/A | N/A | $18.03 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |